alexa The effect of topical bevacizumab on corneal neovascularization.


Journal of Clinical & Experimental Ophthalmology

Author(s): Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI

Abstract Share this page

Abstract PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months. DESIGN: Prospective, nonrandomized, masked observational case series. PARTICIPANTS: Ten eyes of 7 patients with corneal NV. METHODS: Patients received topical bevacizumab (1.25\%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations. RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment. CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects. This article was published in Ophthalmology and referenced in Journal of Clinical & Experimental Ophthalmology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version